Clinical Trial Update: Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on using niraparib before surgery in men with high-risk localized prostate cancer and DNA damage response defects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Marc Dall'Era, MD | Conditions: ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Status: ACTIVE_NOT_RECRUITING